Shares of Twist Bioscience Corp (TWST) tumbled 7.96% in pre-market trading on Monday, despite reporting a surprise profit for its fiscal third quarter. The sharp decline comes as the company's forward guidance failed to meet analyst expectations, raising concerns about its growth trajectory.
Twist Bioscience reported a net income of $0.33 per diluted share for the quarter ended June 30, a significant turnaround from a loss of $1.47 per share in the same period last year. This result handily beat analyst estimates, which had projected a loss of $0.55 per share. Revenue for the quarter came in at $96.1 million, slightly above the $95.6 million forecast by analysts and up from $81.5 million a year earlier.
However, the company's outlook seems to have spooked investors. Twist Bioscience narrowed its fiscal 2025 revenue guidance to a range of $374 million to $376 million, down from its previous forecast of $372 million to $379 million. This new guidance falls short of the $376.5 million analysts were expecting. Furthermore, for the fourth quarter, the company projects revenue between $96 million and $98 million, below the consensus estimate of $99 million. These projections suggest a potential slowdown in growth, which appears to be the primary driver behind the stock's pre-market plunge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.